Researchers developed SNIPRs, innovative receptors that sense soluble ligands, enabling precise therapeutic control in CAR ...

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science ...

PSA responses were seen both in patients with androgen receptor wild type (including androgen receptor amplification) and ligand binding domain mutations, the investigators pointed out. No grade 4 ...

Neoadjuvant immunotherapy offers a survival benefit in specific subtypes of patients but seems to offer no benefit in the ...

In recent years, the integration of biophysical techniques with molecular simulations and artificial intelligence (AI) has revolutionized our understanding of biomolecular and cellular properties.

RVPH READ THE FULL RVPH RESEARCH REPORT Operational and Financial Results On November 14th, 2024, Reviva Pharmaceutical ...

Engineered receptors could lead to more precisely targeted, effective cancer therapies with fewer side effects than existing ...

Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 – – Cash ...

Positive results from completed Phase 2 study of mavorixafor in chronic neutropenia (CN) announced todayPivotal Phase 3 trial of mavorixafor in ...

Detailed price information for Sonnet Biotherapeutics Holdings Inc (SONN-Q) from The Globe and Mail including charting and trades.

Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing ...

Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased ...